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In 2005, the International Society of Nephrology (ISN) established the Global Outreach Program (GO) aimed at building a
capacity for detecting and managing chronic kidney disease and its complications in low- and middle-income countries. Here
we report data from the 2006-2007 screening program (1025 subjects from the general population) in the Republic of Moldova
aimed to determine the prevalence of hypertension, diabetes, and their coexistence with microalbuminuria. The likelihood of a
serious cardiovascular (CV) event was also estimated. Hypertension and diabetes were very common among screened subjects.
The prevalence of microalbuminuria was 16.9% and that of estimated GFR <60ml/min/1.73m2 (decreased renal function) was
9.4%.Male gender was associated with an increased prevalence of hypertension andmicroalbuminuria. Hypertension and diabetes
clustered in subjects with microalbuminuria and renal dysfunction. Risk factors such as preobesity/obesity, physical inactivity
and smoking were relatively common, even in younger participants. The prevalence of subjects with predicted 10-year CV risk
≥10% was 10.0%. In conclusion, in the Republic of Moldova patients with hypertension and diabetes should be screened for the
coexistence of renal abnormalities, with the intention of developing disease-specific health-care interventions with the primary
goal to reduce CV morbidity and mortality and prevent renal disease progression to end stage renal disease.
1. Introduction
The growing global burden of noncommunicable chronic
diseases (NCDs) worldwide has been disregarded until
recently by policy makers, major aid donors, and academics.
However, NCDs are the leading cause of death in the world
[1–3]. In 2008, there were 57million deaths globally of which
63% were due to NCDs. Cardiovascular disease (including
hypertension), diabetes, cancer, and chronic respiratory
disease are the four NCDs prioritized in the Global NCD
Action Plan endorsed by the World Health Assembly in 2012
because they share major behavioral risk factors amenable
to public-health action and are the major contributors to
the global NCD burden. There is also evidence that chronic
kidney disease (CKD) is a key determinant of the poor
health outcomes of hypertension and diabetes and one
of the strongest cardiovascular (CV) risk factors [4]. In
the general population, glomerular filtration rate (GFR)
lower than 60mL/min/1.73m2 and albuminuria—one of
the earliest manifestation of CKD—are associated with an
independent risk of CV morbidity and mortality [5–7].
Nevertheless, data on the prevalence of renal dysfunction and
microalbuminuria from population screening programs are
scarce, especially in low-income countries, where renal and
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CV risk factors, such as hypertension, diabetes, and obesity,
are increasing at an even higher rate than in industrialized
nations [8].
The Republic of Moldova remains the poorest country
in Europe, ranking 111 according to the Global Human
Development Index [9], with CV disease as the main cause of
death [10, 11] and treatment options for patients with NCD
are very limited, especially in rural areas. Renal replacement
therapy (RRT) for end stage renal disease (ESRD) cannot
be oﬀered to all patients due to the shortage of resources.
Since measurements of renal function and albuminuria
are easy and relatively inexpensive, detection programs for
kidney disease and its associated risk factors seem to oﬀer a
valuable opportunity to establish early prevention strategies,
particularly at the primary-care level.
In 2005, the International Society of Nephrology (ISN)
established the Global Outreach Program (GO) (formerly
called the Commission on Global Advancement of Nephrol-
ogy (COMGAN)) aimed at building global capacity for
detecting and managing CKD in low- and middle-income
nations (http://www.theisn.org/). In 2007, the ISN funded
the establishment of an electronic database (Kidney Disease
Data Center (KDDC)) to support the collection and analysis
of data obtained through ISN-sponsored prevention pro-
grams. This program has been developed in the Republic
of Moldova for general population screening, providing
a unique opportunity to assess the prevalence of renal
dysfunction and microalbuminuria in two representative
urban areas of the country.
In the present study we analyzed data from the 2006-
2007 screening program in Moldova with the aim of deter-
mining the prevalence of hypertension, diabetes, and their
coexistence with renal dysfunction andmicroalbuminuria by
using data from the ISN KDDC. Moreover, we estimated the
likelihood of a serious CV event in the same population.
2. Methods
2.1. Study Population. This study is part of the screening
and intervention program Early Detection and Intervention
Program for Chronic Renal and Cardiovascular Disease in
the Republic of Moldova on the behalf of ISN GO in
two representative cities of the country. The screening was
conducted in the general population invited to attend to
two primary health care units in the capital Chisinau and in
Ialoveni. During the period from September 2006 to January
2007, 1025 individuals aged 18 or more participated to the
study (Chisinau: 553, Ialoveni: 472).
2.2. Data Collection. Data were collected prospectively using
an electronic database provided to the Moldova Coordinat-
ing Center in Chisinau by the ISN KDDC based in Bergamo,
Italy. Data quality was monitored by the bioinformatics team
of the Clinical Research Center for Rare Diseases “Aldo
e Cele Dacco,” Bergamo, Italy. In the day of screening,
the participants were enrolled after being informed about
the objectives of the survey and the screening procedure,
as well as potential benefits of the study. Baseline data
obtained from each participant included age, sex, marital
and employment status, education level, smoking status,
alcohol use, physical activity, diabetes mellitus status, and
personal history of hypertension and kidney disease. Family
history of diabetes, hypertension, cardiovascular diseases,
and kidney disease was also collected. Height and weight
were measured and used to calculate body mass index.
Systolic and diastolic blood pressures were measured by
trained personnel using manual sphygmomanometers after
participants rested quietly for five minutes.
Fasting venous blood (creatinine, glucose, cholesterol,
and hemoglobin) and spot urine (albumin, creatinine)
specimens were provided by the participants according
to local protocol. Individuals with microalbuminuria were
asked to proceed with a second confirmatory test a week
apart. Screening was carried out under research protocol
approved in advance by the relevant institutional review
board. All participants gave a written informed consent.
2.3. Definitions. Hypertension was classified according to the
Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure
scheme [12]. Participants were classified as having diabetes
mellitus (DM) if they reported a history of or were currently
treated for DM, or had a fasting blood glucose level
≥126mg/dL. Participants’ body mass index was classified
according to the current World Health Organization (WHO)
[13] scheme as follows: <18.49 kg/m2 (underweight), 18.5–
24.9 kg/m2 (reference range), 25–29.9 kg/m2 (preobese),
and ≥30 kg/m2 (obese). Microalbuminuria was defined as
urinary albumin/creatinine (ACR) values of 30–300mg/g.
Subjects with ACR lower than 30mg/g were defined as
normoalbuminuric, and those with more than 300mg/g
as macroalbuminuric. Urine albumin concentration was
determined by an ELISA method (UBI-MAGIWEL Enzyme
Immunoassay) [14]. Serum creatinine was used to estimate
glomerular filtration rate (GFR) using the 4-variable Mod-
ification of Diet in Renal Disease (MDRD) Study equation
in all participants [15]. Because the MDRD Study equation
is less accurate at higher levels of true GFR, participants were
classified regarding the presence or absence of estimated GFR
(eGFR) <60mL/min/1.73m2 (termed “decreased eGFR”).
The likelihood of a serious CV adverse outcome (death,
myocardial infarction, stroke, heart failure, or coronary
revascularization) during the next 10 years was estimated by
using World Health Organization (WHO) charts.
2.4. Analytical Methods. Descriptive statistics were tabulated
using count and percentage or mean, as appropriate. Missing
values were not imputed and casewise deletion did not occur;
therefore the total number of participants varied by variable.
Outcome of interest included hypertension, diabetes, body
mass index, microalbuminuria, eGFR <60mL/min/1.73m2),
and CV risk, as defined. According to the WHO charts, the
10-year risk of fatal or nonfatal CV event considered the
following parameters: age (years), gender, smoking habit,
SBP (mmHg), cholesterol (mg/dL), and presence/absence of
DM. An SAS version 9.1 code was constructed to generate
International Journal of Hypertension 3
the 10-year CV risk class for each participant. Results
were stratified by age, sex, and microalbuminuria. Statistical
analyses were performed using Stata software, version 12.1
(StataCorp, http://www.stata.com/).
3. Results
3.1. Participant Characteristics. Demographic and clinical
characteristics of the 1025 participants are listed in Table 1.
Mean age of participants was 48 years ranging from
18 to 77 years, and most of them were women (73.3%).
Levels of education were variable, with the highest fraction
of subjects with >10 years of education. Participants reported
mainly working outside the home, but also a large rate of
unemployment. Prevalence of current smoking habit was
higher than 13%, with 35% of men and 5% of women
being current smokers. Among current male smokers,
microalbuminuria was detected in 17.6% of subjects and
GFR <60mL/min/1.73m2 in 4.9%. Alcohol consumption
was variable, but always higher in men than in women. Daily
consumption of fruit and vegetables was common, while
no more than 35% of participants reported daily inactivity
with slight prevalence in women. Positive familiar history for
hypertension and CV disease was relatively high. At physical
examination mean BMI was in the preobese stage both in
men and women, whereas mean blood pressure levels were
within the normal range for both genders.
3.2. Prevalence of Hypertension, Diabetes and Preobesity. The
prevalence of hypertension (assessed at the clinic visit) was
high withmore than 50% of participants having elevated SBP
or DPB or were receiving treatment for previously diagnosed
hypertension. As expected, the prevalence of hypertension
was the highest in participants who were male, and older
than 40 years (Table 2). Overall 62.7% of hypertensive sub-
jects were taking antihypertensive medication. Hypertension
was in general well controlled. 16.1% of participants had
DM. No significant diﬀerence was found in the prevalence
of DM between female and male subjects (Table 2). Seventy-
eight percent of diabetic subjects had hypertension. The
prevalence of DM progressively increased with BMI, and
5.6% of the preobese and 7.8% of the obese were diabetic.
Thirty-seven percent of participants were preobese (assessed
by BMI), with a prevalence lower in female than male.
3.3. Prevalence of Microalbuminuria and eGFR
<60mL/min/1.73m2. The prevalence of microalbuminuria
(assessed at the clinic visit) was 16.9%, higher in participants
older than 40 years (Table 3). Microalbuminuria was
more common in male than female. The prevalence of
eGFR <60mL/min/1.73m2 was 8.2% (Table 3). Higher
prevalence was found in participants who were male and
older than 40 years. The proportion of patients who had
both microalbuminuria or macroalbuminuria and eGFR
<60mL/min/1.73m2 was 2.2%.
3.4. Microalbuminuria in Hypertension and Diabetes. We
analyzed the relationship between microalbuminuria and
hypertension or diabetes according to age groups and
whether eGFR was lower than 60mL/min/1.73m2 (Table 4).
In nondiabetic hypertensive subjects the prevalence of
microalbuminuria was 19.0%. It was higher in participants
with hypertension older than 60 years who had decreased
eGFR (ACR 30–300mg/g: 7.4%). Similarly, in diabetics the
proportion of patients with microalbuminuria was 12.0%.
In this cohort, the prevalence of microalbuminuria progres-
sively increased with age independently of eGFR. Neverthe-
less, microalbuminuria was more frequent in patients with
eGFR <60mL/min/1.73m2 (7.4%) than in those with higher
eGFR (4.6%). Microalbuminuria was detected in 10.9%
of subjects with coexistence of diabetes and hypertension
(Table 4).
3.5. Distribution of Cardiovascular Risk. The prevalence of
participants with predicted 10-year cardiovascular (CV) risk
≥10% was 10.0%. For predicted CV risk 10.1–20%, 20.1–
30%, 30.1–40%, and >40.1%, the proportion of subjects was
5.35%, 3.33%, 0.81%, and 0.81%, respectively.
4. Discussion
The present screening program of a representative cohort of
general population in Moldova showed a very high preva-
lence of hypertension. DM was also common among the
screened participants, together with hypertension clustered
in subjects withmicroalbuminuria, and renal dysfunction. In
accordance with previously published studies, male gender
was associated with an increased prevalence of hypertension,
microalbuminuria and reduced renal function [16–18]. In
addition to disease requiring medical treatment, risk factors
such a pre-obesity/obesity, inactivity, and smoking were
relatively prevalent in the population screened, even in
younger participants. A large proportion of the participants
were unemployed which would favor a sedentary lifestyle
eventually contributing to the high prevalence of pre-obesity
and ultimately of hypertension and DM.
Despite the prevalence of these medical and nonmedical
risk factors, microalbuminuria was present in 10.9% of
subjects with coexistent DM and hypertension. Raised blood
pressure is a key NCD risk factor, and its prevalence, like
that of diabetes, is projected to increase sharply over the
next few decades, especially in low-income countries [19].
Therefore we speculate that—because the epidemic of NCD
is still becoming established in the Republic ofMoldova—the
full impact of these risk factors has not yet been fully realized,
and the prevalence of microalbuminuria and possibly CKD
(defined as eGFR <60mL/min/1.73m2) are likely to increase
substantially during the coming decades, in parallel with
CV disease. This highlights the importance of prevention
because most residents in this country cannot aﬀord renal
replacement therapies and coronary revascularization proce-
dures.
The prevalence of microalbuminuria found in the
present study is higher than that reported by other ISN-
sponsored screening programs in indigent residents of
Guadalajara, Mexico [20], in Nepal [21], and Kinshasa,
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Table 1: Demographics and clinical characteristics of participants in the screening program.
Overall (n = 1025) Women (n = 737) Men (n = 288)
Age (years) 48.8± 14.6 48.7± 14.5 50.0± 14.8
Education (years) 944 673 271
>10 343 (36.3) 231 (34.3) 112 (41.3)
6–10 234 (24.7) 166 (24.7) 68 (25.1)
1–5 312 (33.0) 232 (34.5) 80 (29.5)
None 55 (5.8) 44 (6.5) 11 (4.1)
Work 927 657 270
Physical labor 283 (30.5) 172 (26.2) 111 (41.1)
Oﬃce work 210 (22.6) 157 (23.9) 53 (19.6)
House work 83 (22.6) 72 (11.0) 11 (4.1)
Unemployed 351 (37.8) 256 (39.0) 95 (35.2)
Fruit/Vegetable intake 1018 732 286
1 x/day 545 (53.5) 420 (57.4) 125 (43.7)
3–5 x/day 355 (34.8) 227 (31.0) 128 (44.8)
1 x/week 101 (9.9) 73 (10.0) 28 (9.8)
None 17 (1.6) 12 (1.6) 5 (1.7)
Smoking 1021 734 287
Current 139 (13.6) 37 (5.0) 102 (35.5)
Former 33 (3.2) 5 (0.7) 28 (9.8)
None 849 (83.2) 692 (94.3) 157 (54.7)
Alcohol 1021 735 286
1 x/day 21 (2.1) 7 (1.0) 14 (4.9)
1 x/week 148 (14.5) 61 (8.3) 87 (30.4)
1 x/month 292 (28.6) 208 (28.3) 84 (29.4)
None 560 (54.8) 459 (62.4) 101 (35.3)
Physical activity (min/d) 1007 727 280
>60 372 (36.9) 269 (37.0) 103 (36.8)
30–60 134 (13.3) 82 (11.3) 52 (18.6)
<30 120 (11.9) 88 (12.1) 32 (11.4)
None 381 (37.8) 288 (39.6) 93 (33.2)
Family history
CKD 209 (21.3) 171 (24.2) 38 (13.9)
HTN 498 (50.2) 373 (52.1) 125 (45.3)
DM 157 (16.1) 121 (17.2) 36 (13.1)
Patient’s history
CKD 384 (38.1) 313 (43.2) 71 (25.2)
HTN 480 (47.5) 341 (46.8) 139 (49.5)
DM 125 (12.5) 86 (12.0) 39 (13.9)
MI/CVD 253 (25.2) 186 (25.8) 67 (23.8)
Physical examination
BMI (kg/m2)
1005 724 281
27.72± 5.35 27.9± 6.0 27.4± 4.7
<18.5 61 (6.07%) 49 (6.8) 12 (4.3)
18.5–24.9 254 (25.27%) 177 (24.4) 78 (27.8)
25–29.9 369 (36.72%) 257 (35.5) 111 (39.5)
>30 321 (31.94%) 242 (33.4) 79 (28.1)
Blood pressure (mmHg)
SBP 130.2± 21.3 129.1± 22.2 133.1± 19.3
DBP 83.1± 11.3 82.5± 12.2 85.0± 10.3
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Table 1: Continued.
Overall (n = 1025) Women (n = 737) Men (n = 288)
Laboratory parameters
A/C ratio (mg/g) 20.8± 22.1 20.3± 19.8 22.1± 26.9
eGFR (mL/min/1.73m2) 84.2± 21.3 79.1± 16.8 97.9± 25.6
Data are a number of screened subjects and percent (%) if not otherwise specified. Values for Age, BMI, SBP, DBP, A/C ratio, and eGFR are mean ± SD.
CKD: chronic kidney disease; HTN: hypertension; DM: diabetes mellitus; MI/CVD: myocardial infarction/cardiovascular disease; BMI: body mass index;
SBP: systolic blood pressure; DBP: diastolic blood pressure; A/C: urinary albumin/creatinine ratio; eGFR: estimated glomerular filtration rate.
Table 2: Prevalence of hypertension and diabetes in the Moldova population aged ≥18 years.
Subjects (n) Hypertension∗ Subjects (n) Diabetes◦
All 991 520 (52.4) 959 155 (16.1)
Age (years)
18–39 41 (7.9) 14 (9.0)
40–59 253 (48.8) 69 (44.5)
≥60 224 (43.2) 72 (45.4)
Women 716 369 (51.5) 695 105 (15.1)
Age (years)
18–39 28 (7.6) 8 (7.6)
40–59 182 (49.4) 45 (42.8)
≥60 158 (42.9) 52 (49.5)
Men 275 151 (54.9) 264 50 (18.9)
Age (years)
18–39 13 (8.6) 6 (12.0)
40–59 71 (47.3) 24 (48.0)
≥60 66 (44.0) 20 (40.0)
Data are a number of screened subjects and percent (%) if not otherwise specified. ∗Hypertension is defined as participants with SBP >140mmHg or DBP
>90mmHg, or receiving treatment for previously diagnosed hypertension. ◦Diabetes is defined as participants reporting a history of, or currently treated for
diabetes mellitus, or with fasting blood glucose level ≥126mg/dL.
Table 3: Prevalence of microalbuminuria and decreased GFR.
Subjects ACR∗ Subjects eGFR◦
(n) 30–300mg/g (n) <60mL/min/1.73m2
All 978 166 (16.9) 973 92 (9.4)
Age (years)
18–39 43 (25.9) 5 (2.0)
40–59 68 (40.9) 28 (6.1)
≥60 54 (32.5) 58 (21.9)
Women 702 108 (15.3) 708 78 (11.0)
Age (years)
18–39 31 (28.7) 4 (5.1)
40–59 41 (37.9) 24 (30.7)
≥60 36 (33.3) 50 (64.1)
Men 276 59 (21.3) 265 14 (5.2)
Age (years)
18–39 12 (20.3) 1 (7.1)
40–59 27 (45.7) 4 (28.5)
≥60 18 (30.5) 9 (64.2)
Data are a number of screened subjects and percent (%) if not otherwise specified. ACR: urinary albumin/creatinine ratio. eGFR: estimated glomerular
filtration rate. Microalbuminuria: ACR 30–300mg/g; decreased GFR: eGFR <60mL/min/1.73m2.
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Table 4: Prevalence of microalbuminuria in participants with
hypertension or DM according to age groups and level of renal
function.
ACR (30–300mg/g)∗
Age (years) 18–39 40–59 ≥60 All ages
Hypertension
eGFR (mL/min/1.73m2)
<60 1 (1.1) 4 (4.3) 7 (7.4) 12 (12.8)
≥60 8 (0.9) 25 (2.9) 20 (2.3) 53 (6.2)
Diabetes
eGFR (mL/min/1.73m2)
<60 0 (0.0) 3 (3.2) 4 (4.3) 7 (7.4)
≥60 8 (0.9) 14 (1.6) 17 (2.0) 39 (4.6)
Diabetes + hypertension
eGFR (mL/min/1.73m2)
<60 0 (0.0) 3 (3.3) 4 (4.3) 7 (7.6)
≥60 2 (0.2) 12 (1.4) 15 (1.7) 29 (3.3)
Data are a number of screened subjects and percent (%) if not otherwise
specified. ACR: urinary albumin/creatinine ratio. eGFR: estimated glomeru-
lar filtration rate. Microalbuminuria: ACR 30–300mg/dL. ∗Hypertension
is defined as participants with SBP >140mmHg or DBP >90mmHg,
or receiving treatment for previously diagnosed hypertension. ◦Diabetes
is defined as participants reporting a history of, or currently treated for
diabetes mellitus, or with fasting blood glucose level ≥126mg/dL.
Democratic Republic of Congo [22]. However this highlights
the generalizability of this approach for case detection in
diverse settings around the world. For example, the same
approach has been adopted by the Prevention of Renal
and Vascular ENd-stage Disease (PREVEND) study, a large
European screening program [23].
About 10% of the subjects in the screened population
had an estimated 10% or higher risk of developing a fatal
or nonfatal CV event in the following 10 years. There
is evidence that the increased cardiovascular risk in CKD
patients does not just coexist with hypertension or DM.
Indeed, an independent and progressive association between
GFR and the risk of CV events and deaths has been found
in a community-based study in more than 1 million adult
subjects in the USA [24]. Similarly, a recent study in more
than 6000 people followed on average 7 years has shown
that the risk of cardiovascular death was increased 46% in
subjects with a mild-to-moderate reduction in GFR, inde-
pendent of conventional risk factors such as hypertension
and diabetes [25]. Evidence is also available that the risk of
mortality is better correlated with proteinuria/albuminuria
than with GFR alone [6, 26–28]. A large population-based
study of more than 1 million people from Alberta, Canada,
demonstrated that the presence of proteinuria was associated
with marked increase in the risk of all-cause mortality and
the risk of kidney failure, independent of GFR and at all levels
of baseline kidney function [29]. The association between
proteinuria and CV mortality independent of hypertension,
DM, and GFR has recently been demonstrated in a meta-
analysis of 22 studies [7] including participants with a
wide age range from around the world. The independent
risk associated with albuminuria for all-cause mortality,
CV mortality, and progression to ESRD was confirmed in
over 1.1 million people with proteinuria identified only by
detection of “trace” or greater on dipstick urinalysis, as
well as in over 100,000 who had an albumin creatinine
ratio (ACR) of 10mg/g or more [7]. Thus, considering the
high prevalence of microalbuminuria and renal dysfunction
in the present screening in the Republic of Moldova, the
predicted CV risk at 10 years was probably underestimated.
Long term outcome analysis of the present screened cohort
will clarify whether the inclusion of albuminuria and/or
reduced GFR among the variables considered in algorithms
for the prediction of individual CV risk will improve the
performance of current WHO prediction charts.
Evidence is also emerging that CKD and CV diseases
have a major impact on macroeconomic development due
to diminished labor supply related to premature death and
disability in people of working age. According to WHO,
these conditions decrease the potential annual growth rate
in gross domestic product by 1–5% in low-income countries
experiencing a rapid economic growth [30]. Importantly,
data from large trials have consistently shown that oﬀpatent
drugs such ACE inhibitors can reduce albuminuria and
prevent GFR decline and CV events [31]. Thus, prevention
program should identify subjects whose renal abnormalities
can be treated early at low cost, with the primary goal to
reduce CV mortality and morbidity, which, in turn, may
translate into an economical benefit.
Screening the general population for CKD by measuring
albuminuria and/or serum creatinine has been advocated to
identify and treat those at risk for progressive renal disease,
arguing that most persons with albuminuria and/or reduced
GFR are asymptomatic; however, it is so far considered
premature to recommend in both industrialized and low-
and middle-income countries. On the other hand, screening
in people at increased risk of CKD (so called “selective
screening”) such as those with hypertension and/or DM, in
whom early intervention can slow down the deterioration of
renal function, has receivedmore support [32]. Further stud-
ies, however, are warranted before definite recommendations
for general population or selective screening for CKD can
be provided. Diﬃculties in identifying subjects at increased
risk of CKD in low-income countries should be considered.
Therefore, in this setting, a prescreening phase including
history, blood pressure, and anthropometric values might
allow the identification of patients in whom screening with
blood and urine testing could be most cost eﬀective. There
are also data from low-income countries that a significant
percentage of people younger than 60 years without previous
history of hypertension and diabetes has microalbumin-
uria/proteinuria [21]. Concerns about general population
screenings include not only the cost of the screening itself
but, more importantly, the risk and the cost of treating false
positive subjects with no other modifiable risk factors. Thus,
the first positive test should be always repeated and only
those with confirmed positivity should be treated [33] as was
done with the screening in the Republic of Moldova. When
debating the issue of screening for NCDs, the perspective of
the low- and middle-income countries should be considered
as well as that of the industrialized nations. And, there is not
International Journal of Hypertension 7
a unique blueprint of screening strategy even among low-
income countries, so that the approaches should be adapted
to the conditions and socioeconomic status of each nation
[34].
Our study has some limitations: the study cohort
includes more than double women than men; results from
this screening cannot be taken to infer the absolute or relative
prevalence of hypertension, DM, and renal abnormalities
in the Republic of Moldova, since all subjects were referred
to two centers of the country. However, in consideration
of the limited availability of local resources and relatively
low population of the country, current data seem reasonably
reliable which is supported by the fact that, inline with the
available evidence, the prevalence of microalbuminuria was
higher in subjects with hypertension or DM.
5. Conclusion
We found that hypertension, DM, microalbuminuria, and
impaired kidney function are common within the general
population of the Republic of Moldova. Thus patients with
hypertension or DM should be screened for coexistence of
renal abnormalities. Overall the present data demonstrate
the feasibility of early detection of CKD and associated risk
factors in low-income countries like Moldova. Top priority
for the prevention of NCD including CKD must focus
on eﬀective methods to facilitate physical activity, control
tobacco use, reduce harmful use of alcohol, and promote a
healthy diet. In addition, individual disease-specific health-
care interventions are also required to address those with
hypertension, DM, CKD, or CV disease or at a high risk of
developing these noncommunicable diseases.
Acknowledgments
This study was funded by a Grant from the International
Society of Nephrology (ISN), through the Call for Prevention
Programs on NCDs in low- and middle-income countries of
the ISN GO Research and Prevention Committee.
References
[1] World Health Organization, Preventing Chronic Diseases:
A Vital Investment, World Health Organization, Geneva,
Switzerland, 2005.
[2] Q. L. Zhang and D. Rothenbacher, “Prevalence of chronic kid-
ney disease in population-based studies: systematic review,”
BMC Public Health, vol. 8, article 117, 2008.
[3] M. El Nahas, R. Barsoum, G. Eknoyan et al., “The global
challenge of chronic kidney disease,” Kidney International, vol.
68, no. 6, pp. 2918–2929, 2005.
[4] W. G. Couser, G. Remuzzi, S. Mendis, and M. Tonelli, “The
contribution of chronic kidney disease to the global burden of
major noncommunicable diseases,” Kidney International, vol.
80, no. 12, pp. 1258–1270, 2011.
[5] C. Meisinger, A. Do¨ring, and H. Lo¨wel, “Chronic kidney
disease and risk of incident myocardial infarction and all-
cause and cardiovascular disease mortality in middle-aged
men and women from the general population,” European
Heart Journal, vol. 27, no. 10, pp. 1245–1250, 2006.
[6] H. L. Hillege, V. Fidler, G. F. H. Diercks et al., “Urinary albu-
min excretion predicts cardiovascular and noncardiovascular
mortality in general population,” Circulation, vol. 106, no. 14,
pp. 1777–1782, 2002.
[7] K.Matsushita, M. van der Velde, B. C. Astor et al., “Association
of estimated glomerular filtration rate and albuminuria with
all-cause and cardiovascular mortality in general population
cohorts: a collaborative meta-analysis,” The Lancet, vol. 375,
no. 9731, pp. 2073–2081, 2010.
[8] S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global
prevalence of diabetes: estimates for the year 2000 and
projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–
1053, 2004.
[9] United Nations Development Programme, National Human
Development Report, Chisinau, 2011.
[10] Highlights on health in the Republic of Moldova 2005, Who
Regional Oﬃce for Europe, http://www.EURO.WHO.INT/
DATA/ASSETS/PDF FILE/0003/103566/E88552.pdf.
[11] L. MacLehose, “Health care systems in transition: Republic of
Moldova,” in European Observatory on Health Care Systems,
M. McKee, Ed., vol. 4, Copenhagen, Denmark, 2002.
[12] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The
seventh report of the joint national committee on prevention,
detection, evaluation, and treatment of high blood pressure:
the JNC 7 Report,” Journal of the AmericanMedical Association,
vol. 289, no. 19, pp. 2560–2572, 2003.
[13] World Health Organization, “Obesity: preventing and manag-
ing the global epidemic,” Technical Report 894, World Health
Organization, Geneva, Switzerland, 2000.
[14] B. A. Fielding, D. A. Price, and C. A. Houlton, “Enzyme im-
munoassay for urinary albumin,” Clinical Chemistry, vol. 29,
no. 2, pp. 355–357, 1983.
[15] A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and
D. Roth, “A more accurate method to estimate glomerular
filtration rate from serum creatinine: a new prediction
equation,”Annals of Internal Medicine, vol. 130, no. 6, pp. 461–
470, 1999.
[16] I. Guessous, W. McClellan, S. Vupputuri, and H. Wasse, “Low
documentation of chronic kidney disease among high-risk
patients in a managed care population: a retrospective cohort
study,” BMC Nephrology, vol. 10, no. 1, article 25, 2009.
[17] B. O. Eriksen and O. C. Ingebretsen, “The progression of chro-
nic kidney disease: a 10-year population-based study of the
eﬀects of gender and age,” Kidney International, vol. 69, no.
2, pp. 375–382, 2006.
[18] C. Y. Hsu, C. Iribarren, C. E. McCulloch, J. Darbinian, and A.
S. Go, “Risk factors for end-stage renal disease: 25-year follow-
up,” Archives of Internal Medicine, vol. 169, no. 4, pp. 342–350,
2009.
[19] P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K.
Whelton, and J. He, “Global burden of hypertension: analysis
of worldwide data,” The Lancet, vol. 365, no. 9455, pp. 217–
223, 2005.
[20] J. A. Gutierrez-Padilla, M. Mendoza-Garcia, S. Plascencia-
Perez et al., “Screening for CKD and cardiovascular disease
risk factors using mobile clinics in Jalisco, Mexico,” American
Journal of Kidney Diseases, vol. 55, no. 3, pp. 474–484, 2010.
[21] P. Cravedi, S. Sharma, R. Flores Bravo et al., “Preventing renal
and cardiovascular risk by renal function assessment: insights
from a cross-sectional study in low-income countries and the
US,” BMJ Open, vol. 2, no. 5, Article ID e001357, 2012.
8 International Journal of Hypertension
[22] E. K. Sumaili, J. M. Krzesinski, C. V. Zinga et al., “Prevalence
of chronic kidney disease in Kinshasa: results of a pilot study
from the Democratic Republic of Congo,” Nephrology Dialysis
Transplantation, vol. 24, no. 1, pp. 117–122, 2009.
[23] R. T. Gansevoort, J. C. Verhave, H. L. Hillege et al., “The
validity of screening based on spot morning urine samples
to detect subjects with microalbuminuria in the general
population,” Kidney International, Supplement, vol. 67, no. 94,
pp. S-28–S-35, 2005.
[24] A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y.
Hsu, “Chronic kidney disease and the risks of death, cardi-
ovascular events, and hospitalization,” New England Journal of
Medicine, vol. 351, no. 13, pp. 1296–1370, 2004.
[25] C. S. Fox, P. Muntner, A. Y. Chen et al., “Use of evidence-
based therapies in short-term outcomes of ST-segment ele-
vation myocardial infarction and non-ST-segment elevation
myocardial infarction in patients with chronic kidney disease:
a report from the national cardiovascular data acute coronary
treatment and intervention outcomes network registry,” Cir-
culation, vol. 121, no. 3, pp. 357–365, 2010.
[26] M. Tonelli, N. Wiebe, B. Culleton et al., “Chronic kidney
disease and mortality risk: a systematic review,” Journal of the
American Society of Nephrology, vol. 17, no. 7, pp. 2034–2047,
2006.
[27] S. J. Barbour, L. Er, O. Djurdjev, M. Karim, and A. Levin,
“Diﬀerences in progression of CKD and mortality amongst
Caucasian, Oriental Asian and South Asian CKD patients,”
Nephrology, Dialysis, Transplantation, vol. 25, no. 11, pp. 3663–
3672, 2010.
[28] B. C. Astor, S. I. Hallan, E. R. Miller, E. Yeung, and J. Coresh,
“Glomerular filtration rate, albuminuria, and risk of car-
diovascular and all-cause mortality in the US population,”
American Journal of Epidemiology, vol. 167, no. 10, pp. 1226–
1234, 2008.
[29] B. R. Hemmelgarn, B. J. Manns, A. Lloyd et al., “Relation
between kidney function, proteinuria, and adverse outcomes,”
Journal of the AmericanMedical Association, vol. 303, no. 5, pp.
423–429, 2010.
[30] WHO, Action Plan For the Global Strategy for the Prevention
and Control of Noncommunicable Diseases: Prevent and Control
Cardiovascular Diseases, Cancer, Chronic Respiratory Diseases
and Diabetes, WHO, Geneva, Switzerland, 2008.
[31] P. Ruggenenti and G. Remuzzi, “Time to abandon microalbu-
minuria?” Kidney International, vol. 70, no. 7, pp. 1214–1222,
2006.
[32] A. E. Raﬄe and J. A.M. Gray, “What screening is and is not,” in
Screening: Evidence and Practice, Oxford University Press, New
York, NY, USA, 1st edition, 2007.
[33] M. J. Bottomley, A. Kalachik, C. Mevada, M. O. Brook,
T. James, and P. N. Harden, “Single estimated glomerular
filtration rate and albuminuria measurement substantially
overestimates prevalence of chronic kidney disease,” Nephron,
vol. 117, no. 4, pp. c348–c352, 2011.
[34] N. Chen, C. C. Hsu, K. Yamagata, and R. Langham, “Challeng-
ing chronic kidney disease: experience from chronic kidney
disease prevention programs in Shanghai, Japan, Taiwan and
Australia,”Nephrology, vol. 15, supplement 2, pp. 31–36, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
